IGF-1-induced MMP-11 expression promotes the proliferation and invasion of gastric cancer cells through the JAK1/STAT3 signaling pathway

CHAO SU1,2, WENCHANG WANG2 and CUNCHUAN WANG1

1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630; 2Department of Gastrointestinal Surgery, The Municipal Hospital of Weihai, Weihai, Shandong 264200, P.R. China

Received February 26, 2016; Accepted August 23, 2017

DOI: 10.3892/ol.2018.8234

Abstract. The present study aimed to investigate the association between insulin-like growth factor-1 (IGF-1) and matrix metalloproteinase-11 (MMP-11) expression in gastric cancer (GC) and the underlying mechanisms in SGC-7901 cells. Reverse transcription-quantitative polymerase chain reaction analysis revealed that the expression of IGF-1 and MMP-11 was significantly upregulated in GC tissues compared with normal gastric tissue. Furthermore, IGF-1 significantly and dose-dependently promoted MMP-11. Western blotting revealed that the addition of IGF-1 to SGC-7901 cells led to an evident enhancement in signal transducer and activator of transcription 3 (STAT3), IGF-1R and Janus kinase 1 (JAK1) phosphorylation at 20 and 40 min. A decrease in the extent of the elevated expression of MMP-11 and the enhanced phosphorylation of STAT3, JAK1 and IGF-1 receptor (IGF-1R) induced by IGF-1 in SGC-7901 cells were observed following treatment with NT157 (an IGF-1R inhibitor). Furthermore, piceatannol (a JAK1 inhibitor) or small interfering RNA against STAT3 reduced the extent of the increased expression of MMP-11 induced by IGF-1 in SGC-7901 cells. Piceatannol treatment induced the dose-dependent decline in the enhancement of STAT3 phosphorylation induced by IGF-1, indicating that the JAK1/STAT3 pathway may be implicated in the elevated expression of MMP-11 induced by IGF-1 in SGC-7901 cells. Finally, IGF-1 treatment significantly promoted the proliferation and invasion of SGC-7901 cells, which was inhibited following NT157, piceatannol or si-STAT3 treatment. The present study therefore demonstrated that IGF-1-induced MMP-11 may have facilitated the proliferation and invasion of SGC-7901 cells via the JAK1/STAT3 pathway.

Introduction

Gastric cancer (GC), often diagnosed at advanced stage, is the second-leading cause of cancer-associated mortality worldwide, although its incidence has been substantially declining for the past decades (1,2). GC frequently invades the surrounding tissues to spread cancer cells, leading to high mortality rates for patients suffering from GC (3); understanding the molecular mechanisms of GC invasion and metastasis, including the alterations to metastasis-associated genes, oncogenes, and tumor suppressor genes, may inform potential treatment avenues for patients with GC (4-6). Investigating the molecular mechanisms underlying GC invasion and metastasis, and identifying novel biomarkers involved in GC invasion, has been a focus for cancer research (7-9), but has proven difficult thus far.

Matrix metalloproteinases (MMPs) mediate the degradation of the extracellular matrix to affect tumor cell adhesion and migration. MMPs are upregulated in numerous types of cancer, and their expression is closely associated with the occurrence, invasion and prognosis of cancer (10,11); previous studies have demonstrated that the increased expression of MMPs is associated with the enhanced invasiveness of GC cells, and is associated with poor prognosis in patients with GC (12-14). MMP-11 has been revealed to have a crucial role in the proliferation and invasion of GC, and its expression is associated with the expression of insulin-like growth factor-1 (IGF-1), indicating the presence of a possible association between MMP-11 and IGF-1 in the development and progression of GC (15,16). IGF-1 may stimulate a range of biological processes, including cellular proliferation, differentiation, migration and survival, by binding to the IGF-1 receptor (IGF-1R) (17-19). The altered expression of IGF-1 has been reported in certain tumor types, including in liver and breast cancer, and GC (20-22); however, the specific mechanisms associated with IGF-1 dysregulation have not yet been fully characterized. A recent study demonstrated that IGF-1R knockdown not only suppressed the growth of GC cells via GI cell cycle arrest and apoptosis, but also inhibited cancer cell...
invasion (23). Therefore, in the present study, the expression of IGF-1 and MMP-11 in GC tissues was analyzed, and the specific mechanism underlying GC proliferation and invasion associated with IGF-1 was investigated.

**Materials and methods**

**Reagents.** Recombinant human IGF-1 (25, 50, 100 ng/ml), NT157 (5, 10 µM) and piceatannol (10, 20 µM) were all obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). Different doses of IGF-1 were employed Antibodies against phospho (p)-STAT3 (sc-8059), p-JAK1 (sc-16773), p-JAK2 (sc-21870), p-JAK3 (sc-16567), p-IGFR (sc-81499), β-actin (sc-47778), horseradish peroxidase (HRP) coupled goat anti-mouse IgG (sc-2031) and HRP coupled rabbit anti-goat IgG (sc-2768) secondary antibodies were all purchased from Santa Cruz Biotechnology, Inc. **Clinical specimens.** From September 2008 to November 2011, specimens of GC tissue (male 7, female 3, 58±13.5, n=10), para-carcinoma tissue (male 7, female 3, 58±13.5, n=10), normal gastric tissue (male 7, female 3, 58±13.5, n=10), and gastric ulcer tissue (male 8, female 2, 55.3±15.6, n=10) were collected from the Department of Gastrointestinal Surgery in Renji Hospital (Shanghai, China). The present study was approved by the Institutional Research Ethics Committee of Renji Hospital. Written informed consent was obtained from all participants for the use of tissue samples. None of the patients recruited to the present study had received other anticancer treatments prior to surgery. Sections from each specimen were independently examined by two pathologists, and histological typing was performed using Lauren’s classification (24). Tumor, node and metastasis classification of malignant tumors was assigned in accordance to the International Union Against Cancer (25).

**Cells lines and culture.** The human GC SGC-7901 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., USA) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich; Merck KGaA) and 100 U/ml of penicillin-streptomycin (Sigma-Aldrich; Merck KGaA) at 37°C in a humidified atmosphere with 5% CO₂. SGC-7901 cells at logarithmic phase were cultured with different doses of IGF-1, NT157 or piceatannol for different time (20, 40, and 60 min). The Stat3 siRNA or Scramble siRNA was transfected into SGC-7901 cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) and refined using an RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer's protocols. Samples (1 µg RNA) were reverse-transcribed using a first-strand cDNA synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.). The synthesized cDNA was used for qPCR with the Chromo 4 instrument and SsoFast™ EvaGreen Supermix, and then analyzed with Opticon Monitor Analysis software version 2.0 (all Bio-Rad Laboratories, Inc.; Hercules, CA, USA). Primers used for amplification were as follows: IGF-1 sense: 5'-CAACAGGAAATTCAAAGATGTG-3'; antisense: 5'-ACAGGTAACGCTGACGAAACTGAC-3'; GAPDH sense: 5'-GTGGGTTTGGTGGCCATGG-3'; GAPDH antisense: 5'-GTTGAGATCCGCAAGAGAC-3'; antisense: 5'-AAAGGGTGTACACAACTATA-3'. The PCR cycle included an initial denaturation at 95°C for 10 min followed by 40 cycles of 95°C for 15 sec, and 60°C for 1 min. Specificity was determined by electrophoretic analysis of the reaction products. GAPDH was used as an internal standard. Data were analyzed using the 2⁻ΔΔCT method as described elsewhere (27).

**Western blotting.** Western blotting was performed as previously described (28), with modifications. SGC-7901 cells were harvested in radioimmunoprecipitation assay lysis buffer (Biotek Corporation, Beijing, China) and 35 µg protein per lane was separated by 10% SDS-PAGE mini-gel and transferred to a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA) for 60 min at 100 V. Following incubation in blocking buffer (Tris-buffered saline containing 5% non-fat dry milk, 150 mM NaCl, 50 mM Tris, 0.05% Tween-20, pH 7.5) for 1 h at room temperature, the membrane was hybridized in blocking buffer with the aforementioned primary antibodies against p-STAT3 (1:200), p-IGF-1R (1:500), p-JAK1 (1:200), p-JAK2 (1:500), p-JAK3 (1:200), and β-actin (1:500) overnight at 4°C, then incubated with HRP coupled goat anti-mouse IgG (1:3,000) or rabbit anti-goat IgG (1:5,000) secondary antibodies followed by detection with an enhanced chemiluminescence reagent (GE Healthcare, Chicago, IL, USA). The band densities were analyzed with ImageJ software (version 1.47, National Institutes of Health, Bethesda, MD, USA).

**Cell proliferation and invasion assays.** Cell proliferation and invasion analyses were performed as previously described (29), with alterations. The proliferation ability of SGC-7901 cells was assessed by an MTT spectrophotometric dye assay (Sigma-Aldrich; Merck KGaA) assay. SGC-7901 cells were seeded in 24-well plates at a density of 8x10³ cells per well. The proliferation rate was measured at 0, 24, 48, 72, 96, 120 and 144 h after seeding. Cells were incubated for 4 h in 20 µl MTT at 37°C, and the supernatant was removed. MTT was dissolved by 150 µl well dimethylsulfoxide. The absorbance was determined at 450 nm using a microplate reader.

For cell invasion analysis, transwell chambers (24-well; pore size, 8 µm; BD Biosciences, San Jose, CA, USA) were coated with Matrigel (BD Biosciences) prior to adding the cells (5x10⁵ cells/ml) and incubated at 37°C for 24 h, allowing the gel to solidify. RPMI 1640 with 10% FBS (400 µl) was added to the lower chamber to act as the chemotactic agent.

**RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** RT-qPCR was performed as reported previously (26), with modifications. Briefly, total RNA was extracted from cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and refined using an RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer's protocols. Samples (1 µg RNA) were reverse-transcribed using a first-strand cDNA synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.). The synthesized cDNA was used for qPCR with the Chromo 4 instrument and SsoFast™ EvaGreen Supermix, and then analyzed with Opticon Monitor Analysis software version 2.0 (all Bio-Rad Laboratories, Inc.; Hercules, CA, USA). Primers used for amplification were as follows: IGF-1 sense: 5'-CAACAGGAAATTCAAAGATGTG-3'; antisense: 5'-ACAGGTAACGCTGACGAAACTGAC-3'; GAPDH sense: 5'-GTGGGTTTGGTGGCCATGG-3'; GAPDH antisense: 5'-GTTGAGATCCGCAAGAGAC-3'; antisense: 5'-AAAGGGTGTACACAACTATA-3'. The PCR cycle included an initial denaturation at 95°C for 10 min followed by 40 cycles of 95°C for 15 sec, and 60°C for 1 min. Specificity was determined by electrophoretic analysis of the reaction products. GAPDH was used as an internal standard. Data were analyzed using the 2⁻ΔΔCT method as described elsewhere (27).
Invasive cells on the lower side were fixed with cold methanol (−20°C) for 10 min and then air-dried. Cells were stained with 0.1% crystal violet (dissolved in methanol) for 30 min at room temperature, and then counted using a brightfield microscope at a magnification of x200.

Statistical analysis. All experiments were performed at least three times. Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA). A one-way analysis of variance was performed to determine the differences between multiple groups followed by the Tukey's test. Data were presented as the mean ± standard error of the mean. *P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of MMP-11 and IGF-1 is significantly upregulated in GC tissues. The expression of MMP-11 and IGF-1 was determined in GC, normal gastric, gastric ulcer and para-carcinoma tissue samples using RT-qPCR. The expression of MMP-11 did not differ significantly between normal, gastric ulcer and para-carcinoma tissue samples, whereas it was significantly higher in GC tissues (Fig. 1A; *P<0.05). Fig. 1B illustrates the differences in IGF-1 expression between the four groups. Similarly, no significant alterations to IGF-1 expression were observed between normal gastric, gastric ulcer and para-carcinoma tissue samples, whereas GC tissues exhibited significantly higher expression of IGF-1 (*P<0.05).

IGF-1 elevates the phosphorylation of STAT3, JAK1, and IGF-1R in SGC-7901 cells. Next, the association between IGF-1 and MMP-11 expression in SGC-7901 cells was examined. IGF-1 treatment significantly promoted MMP-11 expression in SGC-7901 cells in parallel with increases in the dose of IGF-1 (*P<0.05; Fig. 2A). Given as the JAK/STAT pathway may be activated in response to a variety of cytokines and growth factors, including epidermal growth factor, interleukin-6 and platelet-derived growth factor (30), western blotting was performed to investigate the time-dependent action of IGF-1 on the phosphorylation of JAK family kinases and STAT3 in SGC-7901 cells. The addition of 50 ng/ml IGF-1 to SGC-7901 cells enhanced the phosphorylation of STAT3, JAK1 and IGF-1R at 20, 40 and 60 min, although this was observed to a lesser extent at 60 min (Fig. 2B). By contrast, the phosphorylation of JAK2 and 3 was not affected following IGF-1 stimulation. These data indicated that STAT3 and JAK1, but not JAK2 and JAK3, were associated with the effect of IGF-1 signaling in SGC-7901 cells.

NT157 reduces the phosphorylation of STAT3, JAK1, and IGF-1R in SGC-7901 cells. Considering the role of IGF-1R in cell proliferation, differentiation, migration and survival following the binding of IGF-1, the IGF-1R inhibitor NT157 was utilized to examine the effect of IGF-1R on MMP-11 expression, and the phosphorylation of STAT3, JAK1 and IGF-1R in SGC-7901 cells. As demonstrated in Fig. 3A, NT157 treatment caused a significant decline in the elevated expression of MMP-11 induced by IGF-1 in SGC-7901 cells that was inversely associated with the concentration of NT157. In addition, the IGF-1-induced phosphorylation of STAT3, JAK1, and IGF-1R was also inhibited in SGC-7901 cells following NT157 treatment (5 µM; Fig. 3B). The results in Fig. 3 indicated that the phosphorylation of STAT3, JAK1 and IGF-1R following IGF-1 treatment was induced by IGF-1R activity in SGC-7901 cells.

JAK1/STAT3 pathway is implicated in the elevated expression of MMP-11 elicited by IGF-1 in SGC-7901 cells. The present study has demonstrated that IGF-1 regulated MMP-11 expression and the phosphorylation of STAT3 and JAK1 in SGC-7901 cells; however, there is limited data regarding the association between IGF-1-induced MMP-11, STAT3 and JAK1 activation. The present study therefore examined the effects of STAT3 and JAK1 on the IGF-1-induced activation of MMP-11 in SGC-7901 cells using piceatannol (a JAK1 inhibitor) and small interfering RNA targeted at STAT3 (si-STAT3). As indicated by Fig. 4A, piceatannol treatment significantly decreased the elevated expression of MMP-11 induced by IGF-1 in SGC-7901 cells in a dose-dependent manner;
the maximal decline in MMP-11 expression was observed following STAT3-knockdown with si-STAT3. Furthermore, the enhanced phosphorylation of STAT3 induced by IGF-1 was reduced in SGC-7901 cells proportional to the concentration of piceatannol (Fig. 4). These results demonstrate the association of the JAK1/STAT3 pathway with the increased expression of MMP-11 induced by IGF-1 in SGC-7901 cells.

**Discussion**

MMP-11 and IGF-1 have been demonstrated to be associated with the proliferation and invasion of GC (15,16); however, the specifics of the interaction between these signaling pathways remain uncharacterized. Although the JAK/STAT pathway serves a role in the progression of GC, the mechanism by which this pathway is associated with the IGF-1-induced proliferation and invasion of GC has not been identified. The present study demonstrated that the expression of IGF-1 and MMP-11 was significantly upregulated in GC tissue relative to normal gastric tissue. IGF-1 induced the expression of MMP-11, as well as the phosphorylation of STAT3, IGF-1R and
JAK1 in SGC-7901 cells. Treatment with an IGF-1R inhibitor reversed the enhanced phosphorylation of STAT3, JAK1 and IGF-1R induced by IGF-1 in SGC-7901 cells. In addition, the JAK1/STAT3 pathway was associated with the increased expression of MMP-11 induced by IGF-1 in SGC-7901 cells. Finally, the present study demonstrated that IGF-1-induced MMP-11 expression may have facilitated the proliferation and invasion of SGC-7901 cells via JAK1/STAT3 pathway.

Zhao et al (15) reported that the increased expression of MMP-11 was associated with an elevation in IGF-1 expression in GC tissues. Kou et al (16) reported that MMP-11 knockdown repressed the proliferative and invasive activities of SGC-7901 cells, with a corresponding decrease in the expression of IGF-1, PCNA and VEGF. The present study reported the increased expression of IGF-1 and MMP-11 in GC tissue compared with non-cancerous tissue, and that IGF-1 treatment induced MMP-11 expression in SGC-7901 cells. The data of the present study concerning IGF-1 and MMP-11 expression in GC tissues are consistent with a previous study (15).

The JAK/STAT pathway regulates cell development and survival. Giorgetti-Peraldi et al (31) identified that insulin promoted the tyrosine phosphorylation of JAK1 in fibroblasts overexpressing the insulin receptor, but did not alter the tyrosine phosphorylation status of JAK2. However, Saad et al (32) demonstrated that insulin stimulated the tyrosine phosphorylation of JAK2 in the insulin-sensitive tissues of rats. Subsequently, Gual et al (33) reported that in mouse fibroblast NIH 3T3 cells overexpressing insulin and IGF-1 receptors, treatment with insulin and IGF-1 resulted in the phosphorylation and activation of JAK1 and JAK2, with JAK1 interacting directly with phosphorylated insulin and IGF-1 receptors. Previous studies have also demonstrated that insulin stimulates the phosphorylation and activation of STAT1, 3 and 5 (34,35). The importance of the JAK/STAT3 pathway in the survival of neurons in response to IGF-1 treatment has also been noted (36). The present study additionally demonstrated that IGF-1 treatment stimulated the phosphorylation of JAK1, STAT3 and IGF-1R in SGC-7901 cells, but not JAK2 or JAK3.
An explanation for the inconsistencies between the present study and Gual et al (33) may be the different cell types employed. We hypothesize that JAK1 and STAT3 are associated with IGF-1-regulated signaling in SGC-7901 cells.

The present study demonstrated that treatment with the IGF-1R inhibitor NT157 reversed the elevated expression of MMP-11 and the phosphorylation of STAT3, JAK1 and IGF-1R as induced by IGF-1 in SGC-7901 cells. NT157 was previously demonstrated to affect IGF-1R and STAT3 in the inhibition of colorectal cancer development (37). Zong et al (38) demonstrated that STAT3, and not STAT5, was activated in response to IGF-1 in 293T cells overexpressing IGF-1R, and that the IGF-1 stimulation of endogenous IGF-1R promoted the tyrosine phosphorylation of STAT3, JAK1 and 2. The specific mediation of STAT3 activation by insulin and IGF-1 receptors has previously been demonstrated (39). A recent study identified that the alterations in cellular behavior induced by IGF-1R and p38 mitogen-activated protein kinase inhibitors were accompanied by alterations to the level of STAT3 in human dental pulp stem cell quiescence, proliferation and differentiation, indicating that STAT3 may be a target for IGF-1R (40).

Quelle et al (41) demonstrated that STATs were direct targets for activated JAKs. Thus, the present study raised the question of the physiological role of JAK1 activation by IGF-1. Shimoda et al (42) reported that the role of JAK1 in STAT activation and receptor phosphorylation could be induced by granulocyte colony-stimulating factor, whereas Sawka-Verhelle et al (43) observed that insulin and IGF-1 caused STAT5B phosphorylation, and that JAKs were not associated with insulin-induced STAT5B activation in Cercopithecus aethiops Cos-7 kidney cells, whereas JAK2 was essential for the activation of STAT5B by growth hormones. The present study revealed that JAK1 and STAT3 were involved in regulating MMP-11 via IGF-1 in SGC-7901 cells. Previous studies have indicated that cell proliferation, invasion and metastasis in certain types of tumor require the involvement of the JAK/STAT pathway (44,45). The JAK1/STAT3 pathway was implicated in the proliferation and invasion of SGC-7901 cells, and it can be inferred that the IGF-1-induced expression of MMP-11 promoted the proliferation and invasion of SGC-7901 cells through the JAK1/STAT3 pathway.

In summary, the results of the present study demonstrated that IGF-1 and MMP-11 expression is significantly upregulated in GC tissues, and that IGF-1 stimulates MMP-11 expression and the phosphorylation of STAT3, IGF-1R and JAK1 in SGC-7901 cells. Furthermore, the elevated expression of MMP-11, and the enhanced phosphorylation of STAT3, JAK1 and IGF-1R induced by IGF-1, are associated with IGF-1R in SGC-7901 cells. Based on these data, it can be concluded that IGF-1-induced MMP-11 expression induces the proliferation and invasion of SGC-7901 cells via the JAK1/STAT3 pathway.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author, on reasonable request.

Authors’ Contributions

CS designed the project and reviewed the manuscript. WW conducted the experiments and drafted the manuscript. CW analyzed the data and drafted the manuscript.

Ethics approval and consent to participate

The present study was approved by the Institutional Research Ethics Committee of Renji Hospital. Written informed consent was obtained from all participants for the use of tissue samples.

Consent for publication

Study participants provided approval for publication.

Competing interests

The authors declare that they have no competing interests.

References

1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunn N: Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015 and incidence by subtype. Eur J Cancer 50: 1330-1344, 2014.
2. Ferlay J, Bray F, Pisani P and Parkin DM: Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press, Lyon, 2001.
3. Velho S, Fernandes MS, Leite M, Figueiredo C and Seruca R: Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol 20: 16433-16442, 2014.
4. Oue N, Aung PP, Mitani Y, Kuniyasu H, Nakayama H and Yasui W: Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology 69 (Suppl 1): S17-S22, 2005.
5. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9: 824-833, 2011.
6. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, et al: Inhibition of gastric invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9: 824-833, 2011.
7. Dun B, Sharma A, Teng Y, Liu H, Parohit S, Xu H, Zeng L and She JX: Mycophenolic acid inhibits migration and invasion of gastric cancer cells via multiple molecular pathways. PLoS One 8: e81702, 2013.
8. Wang L, Guo J, Wang Q, Zhou J, Xu C, Teng R, Chen Y, Wei Q and Liu ZP: LZTFL1 suppresses gastric cancer cell migration and invasion through regulating nuclear translocation of β-catenin. J Cancer Res Clin Oncol 140: 1997-2008, 2014.
9. Zhang ZZ, Shen ZY, Shen YY, Zhao EH, Wang M, Wang CJ, Cao H and Xu J: HOTAIR long noncoding RNA promotes gastric cancer metastasis through suppression of poly r(C)-binding protein (PCBP1) 1. Mol Cancer Ther 14: 1162-1170, 2015.
10. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34, 2006.
11. Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Uruishi M and Huang CL: Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58: 384-391, 2007.
Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. J Clin Cancer 94: 1035-1040, 2006.

Shim KN, Jung SA, Joo YH and Yoo K: Clinical significance of tissue levels of matrix metalloproteins and tissue inhibitors of metalloproteases in gastric cancer. J Gastroenterol 42: 120-128, 2007.

Łąkaszewicz-Zajac M, Mróczko B and Szmitkowski M: Gastric cancer—The role of matrix metalloproteases in tumor progression. Clin Chim Acta 412: 1725-1730, 2011.

Zhao ZS, Chu YQ, Ye ZY, Wang YY and Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol 41: 686-696, 2010.

Kou YB, Zhang SY, Zhao BL, Ding R, Liu H and Li S: Knockdown of its clinicopathologic significance. Oncology 27: 413-424, 2006.

Vandomme J, Touil Y, Ostyn P, Olejniczak C, Flamenco P, El Machhour R, Segard P, Masselot B, Bailillez Y, Formstecher P and Polakowska R: Insulin-like growth factor 1 receptor expression is associated with glandular pathology of the intact rat stomach. J Gastroenterol 42: 1120-1128, 2007.

Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. J Clin Cancer 94: 1035-1040, 2006.

Shim KN, Jung SA, Joo YH and Yoo K: Clinical significance of tissue levels of matrix metalloproteins and tissue inhibitors of metalloproteases in gastric cancer. J Gastroenterol 42: 120-128, 2007.

Łąkaszewicz-Zajac M, Mróczko B and Szmitkowski M: Gastric cancer—The role of matrix metalloproteases in tumor progression. Clin Chim Acta 412: 1725-1730, 2011.

Zhao ZS, Chu YQ, Ye ZY, Wang YY and Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol 41: 686-696, 2010.

Kou YB, Zhang SY, Zhao BL, Ding R, Liu H and Li S: Knockdown of its clinicopathologic significance. Oncology 27: 413-424, 2006.

Vandomme J, Touil Y, Ostyn P, Olejniczak C, Flamenco P, El Machhour R, Segard P, Masselot B, Bailillez Y, Formstecher P and Polakowska R: Insulin-like growth factor 1 receptor expression is associated with glandular pathology of the intact rat stomach. J Gastroenterol 42: 1120-1128, 2007.

Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. J Clin Cancer 94: 1035-1040, 2006.

Shim KN, Jung SA, Joo YH and Yoo K: Clinical significance of tissue levels of matrix metalloproteins and tissue inhibitors of metalloproteases in gastric cancer. J Gastroenterol 42: 120-128, 2007.

Łąkaszewicz-Zajac M, Mróczko B and Szmitkowski M: Gastric cancer—The role of matrix metalloproteases in tumor progression. Clin Chim Acta 412: 1725-1730, 2011.

Zhao ZS, Chu YQ, Ye ZY, Wang YY and Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol 41: 686-696, 2010.

Kou YB, Zhang SY, Zhao BL, Ding R, Liu H and Li S: Knockdown of its clinicopathologic significance. Oncology 27: 413-424, 2006.

Vandomme J, Touil Y, Ostyn P, Olejniczak C, Flamenco P, El Machhour R, Segard P, Masselot B, Bailillez Y, Formstecher P and Polakowska R: Insulin-like growth factor 1 receptor expression is associated with glandular pathology of the intact rat stomach. J Gastroenterol 42: 1120-1128, 2007.

Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. J Clin Cancer 94: 1035-1040, 2006.

Shim KN, Jung SA, Joo YH and Yoo K: Clinical significance of tissue levels of matrix metalloproteins and tissue inhibitors of metalloproteases in gastric cancer. J Gastroenterol 42: 120-128, 2007.

Łąkaszewicz-Zajac M, Mróczko B and Szmitkowski M: Gastric cancer—The role of matrix metalloproteases in tumor progression. Clin Chim Acta 412: 1725-1730, 2011.

Zhao ZS, Chu YQ, Ye ZY, Wang YY and Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol 41: 686-696, 2010.

Kou YB, Zhang SY, Zhao BL, Ding R, Liu H and Li S: Knockdown of its clinicopathologic significance. Oncology 27: 413-424, 2006.

Vandomme J, Touil Y, Ostyn P, Olejniczak C, Flamenco P, El Machhour R, Segard P, Masselot B, Bailillez Y, Formstecher P and Polakowska R: Insulin-like growth factor 1 receptor expression is associated with glandular pathology of the intact rat stomach. J Gastroenterol 42: 1120-1128, 2007.

Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. J Clin Cancer 94: 1035-1040, 2006.